| Synonyms: | |
| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 8406EY2OQA |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C62H88CoN13O14P |
| Molecular Weight | 1329.37 |
| AlogP | None |
| Hydrogen Bond Acceptor | None |
| Hydrogen Bond Donor | None |
| Number of Rotational Bond | None |
| Polar Surface Area | None |
| Molecular species | None |
| Aromatic Rings | None |
| Heavy Atoms | None |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| None | Supplement | DailyMed |
Indications
| Mesh Heading | Maximum Phase | Reference |
|---|---|---|
| Disease; Movement Disorders; Schizophrenia | Phase 2/Phase 3 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 13408-78-1 |
| ChEMBL | CHEMBL4297272 |
| FDA SRS | 8406EY2OQA |
| PubChem | 73415824 |
CONTENTS